Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:APR-246Target |
mutant p53 protein
|
| gptkbp:CEO |
Christian S. Schade
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:focusesOn |
oncology
cancer therapeutics |
| gptkbp:foundedIn |
gptkb:Sweden
|
| gptkbp:foundedYear |
2002
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aprea Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ_Global_Select_Market
|
| gptkbp:notableProduct |
APR-246
|
| gptkbp:numberOfEmployees |
less than 50
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
re-activation of tumor suppressor proteins
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:APRE
|
| gptkbp:website |
https://www.aprea.com/
|
| gptkbp:bfsParent |
gptkb:Lightstone_Ventures
gptkb:5AM_Ventures gptkb:SV_Health_Investors gptkb:Kush_Parmar |
| gptkbp:bfsLayer |
8
|